Investigational cancer drug mimics beneficial effects of fasting in mice

Drug mimics beneficial effects of fasting in mice
An investigational cancer drug that starves tumors of their energy supply also shows evidence of improving whole body metabolism, according to a new study in mice from Washington University School of Medicine in St. Louis. Shown are sections of liver from mice on a high-fat, high-sugar diet. On the left, more white space indicates greater fat accumulation in an untreated mouse. On the right, in a mouse treated with the drug, the liver shows less fat accumulation. Credit: Debosch lab/School of Medicine

An investigational cancer drug that starves tumors of their energy supply also shows evidence of improving whole body metabolism, leading to improved weight control, according to a new study in mice from researchers at Washington University School of Medicine in St. Louis.

The findings are published in the journal Cell Reports Medicine.

In a group of genetically prone to obesity and in a separate group of mice that became obese due to a high-fat, high-sugar diet, treatment with the drug ADI-PEG 20 increased insulin sensitivity, improved cholesterol levels, reduced fat buildup in the liver and lowered inflammation. For the mice genetically prone to obesity from birth, treatment with the drug protected them from their typical weight gain. And for the mice that became obese on a high-fat, high-sugar diet, treatment with the drug caused the mice to lose weight.

The drug is being investigated for potential use as a treatment for a number of cancers, including sarcoma, breast and pancreatic cancers. The drug breaks down the amino acid arginine in the blood, which deprives cancer cells of a key source of fuel. The researchers became interested in studying the drug after finding that genes responsible for breaking down arginine are dialed up tremendously when the body is in a fasting state. They wondered if the drug could mimic this effect of fasting.

Indeed, the researchers found that the drug triggers cells to undergo a process called autophagy, or self-eating, a cellular-level housecleaning process. Cells undergoing autophagy burn their own cellular waste products for fuel. During fasting, when no new fuel is coming from the outside, cells shift to autophagy, turning inward for their fuel supply.

"Giving this drug seems to mimic some of the metabolic and therapeutic effects of fasting," said senior author Brian DeBosch, MD, Ph.D., associate professor of pediatrics. "I was surprised by how large the effect was. In the mice prone to weight gain, the group that received the drug ended up weighing about 25% less than the mice that didn't get the drug. And in the mice on the high-fat, , we saw similar weight loss from the drug. Also, we don't think that the preponderance of the drug's metabolic benefits are from changes in body weight. In fact, for several outcome measures, the metabolic changes preceded significant changes in weight."

The drug has been tested in investigating its safety and efficacy in treating several tumor types, including breast, prostate, pancreatic and liver cancers. In general, metabolic therapies tend to have fewer side effects and are safer than chemotherapy, radiation and even newer immunotherapies used to treat cancer.

DeBosch, a pediatric gastroenterologist who treats patients at St. Louis Children's Hospital, said the research team would like to conduct a clinical trial of the drug to see if it triggers similar metabolic benefits and weight loss in people who are overweight or obese. One question that remains is whether the drug is safe to take long term. It's not a small molecule, like a statin, that can be taken for decades. The is a protein, so there is a possibility that patients could develop an immune response to it over time. However, DeBosch still sees a potential role for such a treatment over a matter of weeks to months.

"Many patients with obesity who are considering bariatric surgery must first lose some weight to make the procedure safer," DeBosch said. "It can be difficult for such patients to lose up to 10% of their body weight before the surgery. This type of therapy could potentially serve as a bridge to help patients lose before , to reduce the risk of complications during and after the procedure."


Explore further

New drug combination could improve glucose and weight control in diabetes

More information: Yiming Zhang et al, Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism, Cell Reports Medicine (2022). DOI: 10.1016/j.xcrm.2021.100498
Journal information: Cell Reports Medicine

Citation: Investigational cancer drug mimics beneficial effects of fasting in mice (2022, January 20) retrieved 28 May 2022 from https://medicalxpress.com/news/2022-01-cancer-drug-mimics-beneficial-effects.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
82 shares

Feedback to editors